70.36 <%= Resources.Global.txtUp %>
Updated 16:40:00
Change % 0.74% Stock price increasing
Change 0.52 Stock price increasing
Volume 206,174
High 70.40
Low 69.36
Open 69.54
ISIN BE0003739530
Prev close 69.84
# of shares 194.51M
Market cap 13,685M EUR

Market closed
Market is closed, opens at 08:00
Price development Latest 1 week 1 month 3 months 6 months 1 year
  70.36 3.6% Stock price increasing 5.3% Stock price increasing 7.7% Stock price increasing 3.0% Stock price increasing 16.4% Stock price increasing
Powered by TradingView

Company profile

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, both of which have lost patent protection. The firm's newer key drugs include Cimzia (rheumatoid arthritis, psoriatic arthritis, and Crohn's disease), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), and Briviact (epilepsy).

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
16 July 2018 21:23:16
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180712.1 - EUROWEB1 - 2018-07-16 22:23:16 - 2018-07-16 21:23:16 - 1000 - Website: OKAY